Detalles de la búsqueda
1.
Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Int J Cancer
; 152(6): 1191-1201, 2023 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36346116
2.
Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.
Curr Treat Options Oncol
; 23(9): 1303-1319, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35976553
3.
Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study.
BMC Cancer
; 21(1): 859, 2021 Jul 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34315431
4.
The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
BMC Cancer
; 20(1): 1018, 2020 Oct 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-33087090
5.
Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.
Aging (Albany NY)
; 16(1): 550-567, 2024 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38194721
6.
The survival after discontinuation of EGFR-TKIs due to intolerable adverse events in patients with EGFR-mutated non-small cell lung cancer.
Thorac Cancer
; 14(4): 348-356, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36525509
7.
Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib.
Thorac Cancer
; 14(25): 2548-2557, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37525557
8.
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
Thorac Cancer
; 14(1): 12-23, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36424878
9.
Generation and validation of a predictive model for estimating survival among patients with EGFR-mutant non-small cell lung cancer.
Am J Cancer Res
; 13(9): 4208-4221, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37818047
10.
Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma.
Cancers (Basel)
; 14(3)2022 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35158940
11.
Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients.
Thorac Cancer
; 13(13): 1888-1897, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35633141
12.
Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI.
Cancers (Basel)
; 14(4)2022 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35205720
13.
Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations.
Anticancer Res
; 42(4): 2145-2157, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35347039
14.
The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: a multi-institutional retrospective study in Taiwan.
Am J Cancer Res
; 12(11): 5342-5350, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36504909
15.
Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients.
Cancers (Basel)
; 14(20)2022 Oct 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36291877
16.
Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
Ther Adv Respir Dis
; 16: 17534666221132731, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36305280
17.
Adjuvant Chemoradiotherapy Associated with Improved Overall Survival in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
Biomedicines
; 10(11)2022 Nov 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36428557
18.
PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC.
Anal Cell Pathol (Amst)
; 2020: 3286139, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33204603
19.
Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy.
Cancers (Basel)
; 12(3)2020 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32155748
20.
Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model.
Cancers (Basel)
; 11(1)2019 Jan 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30634387